Barriers for the development, translation, and implementation of nanomedicine: an African perspective

Saravanan, Muthupandian; Ramachandran, Balajee; Barabadi, Hamed; Giardiello, Marco

doi:10.1002/jin2.43

Cited by 8 publications

(4 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Optimized sharing practices are also needed to promote the translation of nanotechnology from experimental success to clinical practice. [204][205][206][207][208][209]…”

Section: Challenges and Future Perspectivesmentioning

confidence: 99%

Nanotechnology‐Based Targeted Drug Delivery: An Emerging Tool to Overcome Tuberculosis

Baranyai

Soria‐Carrera

Alleva

et al. 2020

Advanced Therapeutics

View full text Add to dashboard Cite

The appearance and rapid spread of drug resistant strains of tuberculosis (TB), one of the deadliest infectious diseases, pose a serious threat to public health and increase the need for shorter, less toxic, and more effective therapies. Developing new drugs is difficult and often associated with side effects, so nanotechnology has emerged as a tool to improve current treatments and to rescue drugs having elevated toxicity or poor solubility. Due to their size and surface chemistry, antimicrobial‐loaded nanocarriers are avidly taken up by macrophages, the main cells hosting Mycobacterium tuberculosis. Macrophages are continuously recruited to infected areas, they can transport drugs with them, making passive targeting a good strategy for TB treatment. Active targeting (decorating surface of nanocarriers with ligands specific to receptors displayed by macrophages) further increases local drug concentration, and thus treatment efficacy. Although in in vivo studies, nanocarriers are often administered intravenously in order to avoid inaccurate dosage in animals, translation to humans requires more convenient routes like pulmonary or oral administration. This report highlights the importance and progress of pulmonary administration, passive and active targeting strategies toward bacteria reservoirs to overcome the challenges in TB treatment.

show abstract

“…Optimized sharing practices are also needed to promote the translation of nanotechnology from experimental success to clinical practice. [204][205][206][207][208][209]…”

Section: Challenges and Future Perspectivesmentioning

confidence: 99%

Nanotechnology‐Based Targeted Drug Delivery: An Emerging Tool to Overcome Tuberculosis

Baranyai

Soria‐Carrera

Alleva

et al. 2020

Advanced Therapeutics

View full text Add to dashboard Cite

show abstract

“…Nanotechnology primarily focusses on "technology transfer," whereby novel techniques are implemented on a conventional treatment regimen to boost the therapeutic process. However, establishing the toxicity and safety profile of these nano-formulations is a daunting task and needs to be investigated further [17].…”

Section: Nanotechnological Approach For Combating Tbmentioning

confidence: 99%

Nano-based anti-tubercular drug delivery: an emerging paradigm for improved therapeutic intervention

Nabi

Rehman

Aggarwal

et al. 2020

Drug Deliv. and Transl. Res.

View full text Add to dashboard Cite

Tuberculosis (TB) classified as one of the most fatal contagious diseases is of prime concern globally. Mycobacterium tuberculosis is the causative agent that ingresses within the host cells. The approved conventional regimen, though the only viable option available, is unfavorably impacting the quality of life of the affected individual. Despite newer antibiotics gaining light, there is an unending demand for more therapeutic alternatives. Therefore, substantial continuous endeavors are been undertaken to come up with novel strategies to curb the disease, the stepping stone being nanotechnology. This approach is instrumental in overcoming the anomalies associated with conventional therapy owing to their intriguing attributes and leads to optimization of the therapeutic effect to a certain extent. This review focusses on the different types of nanocarrier systems that are being currently explored by the researchers for the delivery of anti-tubercular drugs, the outcomes achieved by them, and their prospects.

show abstract

“…Nanotechnology holds great promise to improve human health and is predicted to significantly benefit all human society. (Etheridge et al, ; Chang et al, ; Saravanan et al, ) There has been a rapid global growth of nanomedicine research in recent years, demonstrated by a 280% increase in scientific citations for the term nanomedicine in the last 5 years, and around a 7000% increase in the last 15 years (SciFinder keyword search; nanomedicine [January 2019]). In commercial terms, nanomedicine represents a significant growth area with the global market growth rate of 12.3% predicted to rise to $177.6bn between 2013 and 2019.…”

Section: Nanomedicinementioning

confidence: 99%

Nanomedicines towards targeting intracellular Mtb for the treatment of tuberculosis

Donnellan

Giardiello

2019

J of Interdiscip Nanomed

Self Cite

View full text Add to dashboard Cite

Tuberculosis (TB), caused by Mycobacterium tuberculosis (Mtb), causes the most human deaths than any other diseases from a single infectious agent. Treatments are long and costly and have many associated side effects. Intracellular bacilli are slow growing and difficult to target, which is augmenting the emergence of multi-drug resistance. A hallmark trait of TB is the formation of granulomas, chronic cellular aggregates, which limit bacterial growth but provides a survival reservoir where bacilli may disseminate from. Targeting intracellular Mtb is challenging, but nanomedicine may offer a solution. Nanomedicine is a significantly growing research area and offers the potential for specific disease targeting, dosage reduction, and intracellular drug delivery. This review discusses the application of the various forms of nanomedicine towards targeting of Mtb.

show abstract

Barriers for the development, translation, and implementation of nanomedicine: an African perspective

Cited by 8 publications

References 36 publications

Nanotechnology‐Based Targeted Drug Delivery: An Emerging Tool to Overcome Tuberculosis

Nanotechnology‐Based Targeted Drug Delivery: An Emerging Tool to Overcome Tuberculosis

Nano-based anti-tubercular drug delivery: an emerging paradigm for improved therapeutic intervention

Nanomedicines towards targeting intracellular Mtb for the treatment of tuberculosis

Contact Info

Product

Resources

About